X
Access Company Profiles

Get business overview, business operations details specific to this market, products and services, latest developments and more...

Business Email

Select Companies

 

Plasma Protein Therapeutics Companies

This report lists the top Plasma Protein Therapeutics companies based on the 2023 & 2024 market share reports. Mordor Intelligence expert advisors conducted extensive research and identified these brands to be the leaders in the Plasma Protein Therapeutics industry.

Home Market Analysis Healthcare Research Biotechnology Research Biopharma Research Purified Proteins Research Plasma Therapy Industry Companies

Plasma Protein Therapeutics Top Companies

  1. Octapharma USA Inc.

  2. Takeda Pharmaceutical Company Limited

  3. Biotest UK

  4. Grifols, S.A.

  5. CSL Limited

*Disclaimer: Top companies sorted in no particular order

Plasma Protein Therapeutics Market Major Players

Plasma Protein Therapeutics Market Concentration

Plasma Protein Therapeutics Market Concentration

Plasma Protein Therapeutics Company List

                            • Takeda Pharmaceutical Company Limited

                            • Octapharma USA Inc.

                            • Grifols, S.A.

                            • CSL Limited

                            • Biotest UK

                            • Baxter

                            • Taibang Biological Group Co., Ltd

                            • Kedrion S.p.A

                            • Bio Products Laboratory Ltd

                            • ADMA Biologics, Inc.

                            • Arthrex, Inc.

                            • Johnson and Johnson (DePuy Synthes)


                        Specific to Plasma Protein Therapeutics Market
                        Need More Details On Market Players And Competitors?
                        Download Sample

                        Plasma Protein Therapeutics Market Report Snapshots

                        Plasma Protein Therapeutics Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)